HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 39, 40328-40336, September 24, 2004

This Article Abstract Full Text (PDF) All Versions of this Article: 279/39/40328    most recent M408068200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Visch, H.-J. Articles by Willems, P. H. G. M. Search for Related Content PubMed PubMed Citation Articles by Visch, H.-J. Articles by Willems, P. H. G. M. Social Bookmarking                      What's this?

Inhibition of Mitochondrial Na⁺-Ca²+ Exchange Restores Agonist-induced ATP Production and Ca²+ Handling in Human Complex I Deficiency^*

Henk-Jan Visch¶||, Guy A. Rutter**, Werner J. H. Koopman¶, Jan B. Koenderink¶, Sjoerd Verkaart¶||, Theun de Groot¶, Aniko Varadi**, Kathryn J. Mitchell**, Lambert P. van den Heuvel||, Jan A. M. Smeitink||¶¶, and Peter H. G. M. Willems¶

From the Departments of Biochemistry and Pediatrics and the Microscopical Imaging Center, Nijmegen Centers of ^¶Molecular Life Sciences and ^||Mitochondrial Disorders, University Medical Center Nijmegen, NL-6500 HB Nijmegen, The Netherlands and the ^**Henry Wellcome Signalling Laboratories and Department of Biochemistry, University of Bristol, BS8 1TD Bristol, United Kingdom

Received for publication, July 16, 2004

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Human mitochondrial complex I (NADH:ubiquinone oxidoreductase) of the oxidative phosphorylation system is a multiprotein assembly comprising both nuclear and mitochondrially encoded subunits. Deficiency of this complex is associated with numerous clinical syndromes ranging from highly progressive, often early lethal encephalopathies, of which Leigh disease is the most frequent, to neurodegenerative disorders in adult life, including Leber's hereditary optic neuropathy and Parkinson disease. We show here that the cytosolic Ca²⁺ signal in response to hormonal stimulation with bradykinin was impaired in skin fibroblasts from children between the ages of 0 and 5 years with an isolated complex I deficiency caused by mutations in nuclear encoded structural subunits of the complex. Inhibition of mitochondrial Na⁺-Ca²⁺ exchange by the benzothiazepine CGP37157completely restored the aberrant cytosolic Ca²⁺ signal. This effect of the inhibitor was paralleled by complete restoration of the bradykinin-induced increases in mitochondrial Ca²⁺ concentration and ensuing ATP production. Thus, impaired mitochondrial Ca²⁺ accumulation during agonist stimulation is a major consequence of human complex I deficiency, a finding that may provide the basis for the development of new therapeutic approaches to this disorder.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Human mitochondrial complex I (NADH:ubiquinone oxidoreductase) is the largest multisubunit assembly of the oxidative phosphorylation (OXPHOS)¹ system, comprising 39 nuclear encoded and seven mitochondrially encoded subunits. Malfunction of this complex is associated with a wide variety of clinical syndromes ranging from often early lethal disorders, of which Leigh disease, a progressive encephalopathy, is the most frequent, to neurodegenerative disorders in adulthood, including Leber's hereditary optic neuropathy and Parkinson disease. In recent years, all human nuclear structural complex I genes have been characterized, which allowed us to elucidate the genetic defect in 40% of a cohort of complex I-deficient patients in which the enzyme defect was present in at least skeletal muscle and cultured skin fibroblasts (1–7). To enhance our understanding of the pathophysiological consequences of these diseases, with the final aim of developing new treatment strategies to stabilize or even cure these conditions, we study genetically characterized human complex I-deficient fibroblast cell lines as a model for OXPHOS system disease, knowing that these cells are glycolytic (8). Several hypotheses concerning the pathophysiology of OXPHOS diseases have been investigated of which the most consistent are (a) increased production of reactive oxygen species (9), (b) decreased potential across the mitochondrial inner membrane (10), (c) decreased intracellular ATP levels (11–13), and (d) altered Ca²⁺ homeostasis (10, 12). In agreement with the reactive oxygen species hypothesis (a), we found that metallothioneins were up-regulated in all of the genetically characterized complex I-deficient cell lines (14). Pilot experiments with these cell lines furthermore revealed that human complex I deficiency was associated with altered cytosolic Ca²⁺ homeostasis. This encouraged us to undertake a detailed analysis of ATP production and calcium handling in a skin fibroblast cell line derived from a Leigh disease patient harboring a homozygous missense mutation (G364A) in the nuclear NDUFS7 gene (4). Expression of this specific mutation in Yarrowia lipolytica confirmed the deleterious effect on complex I enzyme activity (15). The human NDUFS7 protein is one of the most conserved subunits of complex I and plays a central role in the interaction with the electron acceptor ubiquinone and in the proton-translocating mechanism (16, 17). Here we show that altered cytosolic Ca²⁺ handling in complex I-deficient cells with a mutation in the NDUFS7 gene is associated with reduced mitochondrial Ca²⁺ accumulation and consequent ATP synthesis. An acute rescue of the defects was achieved following treatment with CGP37157 a benzothiazepine specifically inhibiting mitochondrial Na⁺-Ca²⁺ exchange.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Chemicals—Culture material was obtained from Invitrogen, and fluorescent dyes were from Molecular Probes Inc. (Leiden, The Netherlands). CGP37157was purchased from Tocris Cookson Ltd. (Avonmouth, Bristol, UK), and all other reagents were from Sigma.

Patient Fibroblasts—Fibroblasts were derived from skin biopsies of four healthy subjects and eight patients in the age range of 0–5 years in whom an isolated enzymatic complex I deficiency had been confirmed in both muscle tissue and cultured fibroblasts. The patient cells carried mutations the NDUFS1,² NDUFS2 (1), NDUFS4 (2, 3), NDUFS7 (4), or NDUFV1 (6) gene. Skin fibroblasts were cultured in M199 medium containing 5 mg/liter Tween 20 and supplemented with 10% fetal calf serum, 100 IU/ml penicillin, and 100 IU/ml streptomycin.

Fluorescence Imaging of Cytosolic Ca²⁺—Fibroblasts were seeded on 22-mm glass coverslips, grown to subconfluence for 24 h, and loaded with Fura-2 in the presence of 3 µM Fura-2/AM for 25 min at 37 °C. After removal of excess dye, the coverslip was mounted in a thermostatic (37 °C) perfusion chamber placed on the stage of an inverted microscope (Nikon Diaphot). Dynamic video imaging was carried out using the MagiCal hardware and Tardis software as described previously (18). Cells were perfused with Hepes-Tris medium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 5.5 mM D-glucose, and 10 mM Hepes, pH 7.4), supplemented with an amino acid mixture according to Eagle, and challenged with 1 µM bradykinin to increase the cytosolic free Ca²⁺ concentration ([Ca²⁺]_C). The Fura-2 fluorescence emission ratio at 492 nm was monitored as a measure of [Ca²⁺]_C after alternating excitation at 340 and 380 nm. The kinetics with which the fluorescence emission ratio decreased was fitted to a monoexponential equation, R(t) = R(t = 0)·e^{–· t} + R(P), where is the decay constant (in s) and R(P) is the poststimulatory level to which R declines. From the half-time (t ) was calculated using the equation t (s) = –ln(0.5)·.

Luminescence Monitoring of Cytosolic ATP, Endoplasmic Reticular Ca²⁺, and Mitochondrial Ca²⁺ and ATP—Because primary human skin fibroblasts are refractory to most conventional transfection protocols, we used an adenoviral system to express mitochondrially targeted aequorin (AdCMVmAq), mitochondrially targeted luciferase (AdCMVmLuc), and cytosolic luciferase (AdCMVcLuc) (19, 20), whereas a baculoviral system was used to express endoplasmic reticulum-targeted aequorin (BvCMVeAq). The latter system, which is normally used for protein production in Spodoptera frugiperda 9 insect cells, was made suitable for protein expression in mammalian cells by first removing the herpes simplex virus thymidine kinase polyadenylation signal from the pFastBacTMDual vector (Invitrogen) using AccI and XhoI, by next, after blunting and ligation, removing both the p10 and polyhedron promoter with SmaI and XbaI, and by replacing it with the coding region of a cytomegalovirus (CMV) promoter digested from the pcDNA1 vector (Invitrogen) using NruI and XbaI. Finally, the cDNA of ER-targeted aequorin was digested from the erAEQmut/pcDNA1 vector described by Montero et al. (21) with KpnI and NsiI and ligated behind the CMV promoter in the KpnI and PstI restriction sites of the modified baculovirus vector. Approximately 25,000 cells were spotted on a 13-mm coverslip, and after 24 h cells were infected with the appropriate virus and cultured for another 48 h. In case of baculoviral infection, the culture medium contained 1.75 mM sodium butyrate for proper expression of the photoprotein.

Luciferase luminescence was monitored continuously using a photomultiplier tube (Thorn EMI Electron tubes, Ruislip, Middlesex, UK) (19). Cells were perfused (2 ml·min^–1) with modified Krebs-Ringer bicarbonate medium (KRB; 140 mM NaCl, 3.5 mM KCl, 0.5 mM NaH₂PO₄, 0.5 mM MgSO₄, 10 mM Hepes, 2 mM NaHCO₃, 1 mM CaCl₂, 5.5 mM D-glucose, pH 7.4) containing 5 µM beetle luciferin (Promega, Madison, WI) at 37 °C. Emitted light was collected with a photoncounting board using the supplier's software (Thorn EMI) (22). Light output was recorded at 1-s intervals after which the traces were smoothed off-line by using a 5-point moving average (Origin Pro 6.1, OriginLab Corporation, Northampton, MA). Typically, light output from a coverslip of virally infected fibroblasts was 1,000–25,000 counts·s^–1 versus a background of 10 counts·s^–1. The same system was used to monitor aequorin luminescence. Mitochondrial aequorin was reconstituted with 5 µM coelenterazine (Molecular Probes) in KRB for 1 h at 37 °C. Light output was recorded at 1-s intervals, and at the end of each experiment the signal was calibrated by lysing the cells with 100 µM digitonin and 10 mM CaCl₂ to determine the total photoprotein content. Aequorin photon emission was converted off-line into [Ca²⁺] values using a computer algorithm based on the Ca²⁺ response curve of wild-type aequorin (23). For measurements of endoplasmic reticulum aequorin, we first reduced the Ca²⁺ content of this organelle by incubating the cells with a reversible inhibitor of the ER Ca²⁺-ATPase, BHQ (10 µM), in Ca²⁺-free KRB (no CaCl₂ added and 0.5 mM EGTA present) for 10 min. After washing, endoplasmic reticulum aequorin was reconstituted with 5 µM coelenterazine n (Molecular Probes) in Ca²⁺-free KRB containing 10 µM BHQ for 1.5 h at room temperature. Next, the glass coverslip was placed in the luminometer, and cells were initially perfused with Ca²⁺-free KRB for 5 min at 37 °C to remove BHQ.

To determine the sarco(endo)plasmic reticulum Ca²⁺-ATPase (SERCA)-mediated Ca²⁺ uptake activity, cells were perfused with a Ca²⁺-free intracellular medium (10 mM Hepes, 120 mM KCl, 5 mM NaCl, 2.5 mM MgCl₂, 2 mM EGTA, 2.5 mM ATP, pH 7.05) containing 20 µg/ml saponin for 2 min at 37 °C to selectively permeabilize the plasma membrane (24). SERCA-mediated Ca²⁺ uptake into the ER was started by perfusing with intracellular medium containing 0.55 mM CaCl₂ (free Ca²⁺ concentration of 0.1 µM). The luminescence data were calibrated as described previously by Alvarez and Montero (25).

Fluorescence Imaging of Mitochondrial Membrane Potential (_M)— Fibroblasts were loaded with 0.5 µM JC-1 for 10 min. Next, coverslips (22 mm) were mounted in a perfusion chamber and placed on the stage of an inverted microscope (Axiovert 200 M, Carl Zeiss, Jena, Germany) equipped with a x40, 1.3 NA F Fluar objective. Cells were perfused with KRB. JC-1 was excited at 488 nm using a monochromator (Polychrome IV, TILL Photonics, Gräfelfing, Germany). Fluorescence light was directed by a 505DRLPXR dichroic mirror (Omega Optical Inc., Brattleboro, VT) through either a 535AF26 (JC-1 monomers, green emission) or a 565ALP emission filter (JC-1 aggregates, red emission) (Omega) onto a CoolSNAP HQ monochrome CCD camera (Roper Scientific, Vianen, The Netherlands). All hardware was controlled with Metafluor 6.0 software (Universal Imaging Corporation, Downingtown, PA) running under Windows XP Professional on a personal computer equipped with 1-gigabyte random access memory (RAM). Images were digitalized, and the amount of J-aggregates/cell was automatically counted using Image Pro Plus 4.1 software (Media Cybernetics, Silver Spring, MD).

Determination of ATP Levels in Cell Homogenates—Pellets containing 300,000 cells were immediately frozen in liquid nitrogen and subsequently resuspended in 1 ml of phosphate-buffered saline on ice. For determination of the total ATP content, a commercial kit was used based on luciferase (Roche Applied Science). Bioluminescence signals were measured with a Berthold MicroLumat Plus LB 96-V luminometer and expressed per mg of protein as determined using the Bio-Rad protein assay.

Data Analysis—Numerical values were visualized using Origin Pro 6.1 (OriginLab Corporation), and values from multiple experiments were expressed as average ± S.E. Statistical significances were assessed by Student's t test.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Impaired Cytosolic Ca²⁺ Handling in Complex I-deficient Human Fibroblasts—The present study was aimed at establishing the consequences of complex I deficiency on intracellular Ca²⁺ homeostasis in the context of the genetic background of the patient. Skin fibroblasts from four control individuals and eight patients with isolated enzymatic complex I deficiency caused by nuclear DNA mutations were loaded with the fluorescent Ca²⁺ indicator Fura-2 for monitoring of the bradykinin-induced changes in [Ca²⁺]_C in individual cells using digital imaging microscopy. An increase in [Ca²⁺]_C is reported by an increase in the ratio of the fluorescence emission intensities at excitation wavelengths of 340 and 380 nm.

Control fibroblasts displayed resting emission ratios of 0.48 ± 0.02 (n = 24), 0.48 ± 0.02 (n = 31), 0.54 ± 0.03 (n = 30), and 0.52 ± 0.02 (n = 29) that were not significantly different between the four individuals. Immediately after stimulation with bradykinin (1 µM) the cells displayed a sharp rise in [Ca²⁺]_C (see also Fig. 3D). Maximum increases in the emission ratio were 4.47 ± 0.15 (n = 24), 4.71 ± 0.19 (n = 31), 4.89 ± 0.19 (n = 30), and 4.74 ± 0.15 (n = 29) x base line and did not statistically differ. The amplitude of the [Ca²⁺]_C rise was independent of extracellular Ca²⁺, demonstrating that Ca²⁺ ions entered the cytosolic compartment from the endoplasmic reticular Ca²⁺ store. After having reached its maximum, [Ca²⁺]_C more gradually declined again to prestimulatory levels. The decrease in fluorescence emission ratio was fitted monoexponentially, and half-times (t) were 12.6 ± 0.5s(n = 24), 13.4 ± 0.5 s (n = 31), 13.4 ± 0.5 s (n = 30), and 14.1 ± 0.6 s (n = 29), suggesting the involvement of one major Ca²⁺ removal process. The t values did not significantly differ between the four healthy individuals. On average, control fibroblasts (n = 114) displayed an emission ratio of 0.50 ± 0.01 at rest that increased to 4.71 ± 0.09 x base line following stimulation with bradykinin and subsequently decreased with a t of 13.4 ± 0.3 s.

View larger version (36K): [in this window] [in a new window]   FIG. 3. Restoration of impaired Ca2+ and ATP handling in complex I-deficient fibroblasts by CGP37157 Cells were incubated in the absence (A–D) or presence (E–H) of CGP37157(1 µM) for 2 min and stimulated with bradykinin (1 µM) at the indicated time. Bradykinin-induced changes in cytosolic and mitochondrial [Ca2+] and [ATP] were monitored by either luminometry (A–C and E–G) or fluorometry (D and H). In each ATP measurement (B, C, F, and G), the luminescence signal was expressed relative to its prestimulatory value. Depicted are averaged traces of the number of coverslips (A–C and E–G) and cells (D and H) given in the text. Details on the quantitative analysis of the signals are given in the text. cLuc, cytosolic luciferase; mLuc, mitochondrially targeted luciferase.

View larger version (21K): [in this window] [in a new window]   FIG. 1. Impaired cytosolic Ca2+ handling in complex I-deficient fibroblasts. Fura-2-loaded control and patient fibroblasts were challenged with 1 µM bradykinin, and the changes in [Ca2+]C were monitored by digital imaging microscopy. For kinetic analysis, the fluorescence emission ratio was normalized to its prestimulatory value. The peak [Ca2+]C increase (maximal increase in fluorescence emission ratio) and cytosolic Ca2+ removal rate (half-time of the decrease in fluorescence emission ratio) in control fibroblasts were set at 100%, to which all patient values were related. A linear fit, during which the S.E. of each data point was used as a weight (weight = 1/(S.E.)2), was performed to determine the correlation between both parameters. a, significantly different from the Ca2+ removal rate in control fibroblasts; b, significantly different from the peak [Ca2+]C increase in control fibroblasts. Cell numbers and p values are given in the text.

Reduced Filling State of the Endoplasmic Reticular Ca²⁺ Store in Unstimulated Complex I-deficient Fibroblasts—The bradykinin-induced [Ca²⁺]_C transients in fibroblasts are likely to be shaped mainly by the relative rates of (i) Ca²⁺ release from the ER into the cytoplasm, (ii) Ca²⁺ uptake and subsequent release by mitochondria, and (iii) cytosolic Ca²⁺ removal via SERCAs and plasma membrane Ca²⁺-ATPases. To investigate whether the ER Ca²⁺ content is altered in resting patient fibroblasts with a G364A mutation in the NDUFS7 gene, cells were loaded with Fura-2 and subsequently treated with the Ca²⁺ ionophore ionomycin. Measurements were performed in the absence of extracellular Ca²⁺ to prevent capacitative Ca²⁺ entry in response to Ca²⁺ store depletion. Ionomycin (1 µM) transiently increased [Ca²⁺]_C in both control and patient fibroblasts (Fig. 2A). The area under the peak was 20% lower in patient fibroblasts (Fig. 2A, 79 ± 2%, n = 19; p < 0.001), indicating that the Ca²⁺ content of the ER is significantly reduced in complex I deficiency. Reduction of the ER Ca²⁺ content may point to a decreased rate of Ca²⁺ uptake or an increased rate of Ca²⁺ leakage.

View larger version (15K): [in this window] [in a new window]   FIG. 2. Reduced filling state of the internal Ca2+ store in complex I-deficient fibroblasts. Fura-2-loaded control and patient fibroblasts were treated with 1 µM ionomycin (A) or 10 µM BHQ (C), and changes in [Ca2+]C were monitored by digital imaging microscopy. Measurements were performed in the absence of external Ca2+ (no CaCl2 added and 0.5 m EGTA present). In each experiment, the fluorescence emission ratio was normalized to its prestimulatory value. Depicted are averaged traces of the number of cells given in the text. Control and patient fibroblasts expressing ER-targeted aequorin were permeabilized by saponin treatment to determine the rate of SERCA-mediated Ca2+ uptake and the Ca2+ uptake capacity of the internal Ca2+ store (B). Permeabilized fibroblasts were perfused with a Ca2+-free intracellular medium (no CaCl added and 2.0 mM EGTA present) containing 2.5 mM ATP. At the indicated time, SERCA-mediated Ca2+ uptake into the ER was started by increasing the free Ca2+ concentration in the perfusion medium to 0.1 µM. Depicted are typical traces of control and patient coverslips. Details on the quantitative analysis of the signals are given in the text.

To address the possibility that Ca²⁺ leakage from the ER is increased in patient fibroblasts, cells were loaded with Fura-2 and subsequently treated with the SERCA inhibitor BHQ in the absence of extracellular Ca²⁺. Both in control and patient fibroblasts, BHQ (10 µM) evoked an immediate increase in [Ca²⁺]_C (Fig. 2C). The maximal rate of [Ca²⁺]_C increase was not significantly different between control (0.016 ± 0.001 arbitrary unit·s^–1, n = 13) and patient (0.016 ± 0.001 arbitrary unit·s^–1, n = 16) fibroblasts. In contrast, the peak [Ca²⁺]_C was significantly (p < 0.001) lower in patient (1.42 ± 0.01 x base line) as compared with control fibroblasts (1.58 ± 0.01 x base line). The latter finding is compatible with a decreased ER Ca²⁺ content in resting complex I-deficient fibroblasts. Finally, measurement of the total ATP content in whole cell lysates using a luciferase-based assay revealed a small (5%) but statistically insignificant decrease in patient fibroblasts (p = 0.08; n = 4 for both control and patient fibroblasts).

Decreased Mitochondrial Ca²⁺ Accumulation in Bradykinin-stimulated Complex I-deficient Fibroblasts—It has been shown previously that agonist-induced increases in [Ca²⁺]_C lead to parallel increases in the total (26) and free (27, 28) concentration of Ca²⁺ in mitochondria ([Ca²⁺]_M). To investigate whether mitochondrial Ca²⁺ accumulation is altered in complex I deficiency, patient fibroblasts were infected with adenoviruses expressing mitochondrially targeted aequorin. The cells (25,000) were challenged with 1 µM bradykinin, and the changes in [Ca²⁺]_M were monitored. The peak increase in [Ca²⁺]_M, which was observed at 12 s after the onset of stimulation, was significantly (p < 0.05) decreased from 4.23 ± 0.21 µM (n = 6) in control cells to 3.36 ± 0.20 µM (n = 6) in patient cells (Fig. 3A). The t values of the [Ca²⁺]_M decrease did not differ between control (6.0 ± 0.5 s) and patient (6.5 ± 0.3 s) fibroblasts.

Pretreatment of the cells with the protonophore FCCP (1 µM, 2 min) completely abolished the bradykinin-induced increase in [Ca²⁺]_M. In contrast, the drug inhibited the bradykinin-induced peak increase in [Ca²⁺]_C only by 25% (see also Fig. 4A). This demonstrates that aequorin was exclusively present in the mitochondrial compartment.

View larger version (28K): [in this window] [in a new window]   FIG. 4. Restorative effect of CGP37157depends on M. Fura-2-loaded cells were stimulated with bradykinin (1 µM; A and B) or treated with ionomycin (1 µM; C) in the absence and presence of CGP37157(1 µM) and/or FCCP (1 µM) added 2 min prior to stimulation. Measurements were performed in the absence of external Ca2+ (no CaCl2 added and 0.5 mM EGTA present). Shown is the effect on the bradykinin-induced peak increase in [Ca2+]C (A), the half-time of the cytosolic Ca2+ decrease (B), and the ER Ca2+ content in resting fibroblasts (C). The averaged value of untreated controls is set at 100%, to which all values are related. Fibroblasts expressing either mitochondrially targeted (mLuc; D and F) or cytosolic luciferase (cLuc; E and F) were treated with FCCP (1 µM) for the indicated period of time. The effect on the mitochondrial (D) and the cytosolic luminescence signal (E) is shown. In each measurement, the luminescence signal was expressed relative to its value before FCCP treatment. The mitochondrial and cytosolic luminescence level at 2 min after the onset of FCCP treatment is shown in F. The averaged value of FCCP-treated controls is set at 100%, to which the corresponding patient values are related. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Reduced Mitochondrial ATP Production in Bradykinin-stimulated Complex I-deficient Fibroblasts—Agonist-induced increases in [Ca²⁺]_M have been shown previously to cause activation of intramitochondrial dehydrogenases (33, 34) and consequent increases in NAD(P)H and FADH₂ (35, 36). This in turn stimulates respiratory chain activity and mitochondrial ATP synthesis (12, 37). To investigate whether mitochondrial ATP production is altered in complex I deficiency, patient fibroblasts were infected with adenoviruses expressing mitochondrially targeted or cytosolic firefly luciferase. Bradykinin evoked a gradual increase in both [ATP]_M (Fig. 3B) and [ATP]_C (Fig. 3C) that lasted 40 s and started 20 s after the onset of stimulation and 8 s after [Ca²⁺]_M had reached its maximum. Subsequently, the ATP concentrations more gradually decreased again to prestimulatory levels. Pretreatment of cells expressing mitochondrially targeted luciferase with the mitochondrial ATP synthase inhibitor oligomycin (10 µM, 10 min) resulted in complete inhibition of the bradykinin-induced increase in luminescence (data not shown). With respect to [ATP]_M, both rising speed and peak value were significantly (p < 0.01) decreased in patient fibroblasts (rising speeds of 0.33 ± 0.05%·s^–1 and 0.14 ± 0.02%·s^–1 and peak values of 109.3 ± 0.8% and 104.5 ± 1.0% for control (n = 7) and patient (n = 5) cells, respectively). Regarding the bradykinin-induced increase in [ATP]_C, however, the rising speed and peak value did not significantly differ between control and patient fibroblasts (rising speeds of 0.18 ± 0.03%·s^–1 and 0.11 ± 0.01%·s^–1 and peak values of 104.7 ± 0.8% and 103.0 ± 0.6% for control (n = 3) and patient (n = 3) cells, respectively).

Fig. 3D compares the bradykinin-induced changes in [Ca²⁺]_C between Fura-2-loaded control and patient fibroblasts. In both cases, the peak increase in [Ca²⁺]_C was observed 8 s after the onset of stimulation. The amplitude of the [Ca²⁺]_C rise was significantly (p < 0.01) decreased in patient fibroblasts (maximum emission ratios of 5.7 ± 0.2 and 4.6 ± 0.1 x base line for control (n = 17) and patient (n = 30) cells, respectively). The t of the subsequent [Ca²⁺]_C decline was significantly (p < 0.001) increased in patient fibroblasts (t values of 11.8 ± 0.6 s and 18.2 ± 1.0 s for control (n = 17) and patient (n = 30) cells, respectively).

Restoration of Impaired Ca²⁺ and ATP Homeostasis by CGP37157in Human Complex I-deficient Fibroblasts—It has been demonstrated that cells of a cybrid cell line of ⁰-osteosarcoma cells and enucleated cytoplasts from a patient with the tRNA^Lys mutation of myoclonic epilepsy with ragged red fibers (MERRF) display impaired mitochondrial, but not cytosolic, Ca²⁺ handling following agonist stimulation (12). The same study showed that mitochondrial Ca²⁺ handling and the ensuing stimulation of ATP production were largely restored with CGP37157 a specific inhibitor of mitochondrial Na⁺-Ca²⁺ exchange (38). To investigate whether this drug exerts restorative effects in complex I-deficient fibroblasts, we pretreated control and patient cells with 1 µM CGP37157for 2 min and monitored the bradykinin-induced changes in [Ca²⁺]_M (Fig. 3E), [ATP]_M (Fig. 3F), [ATP]_C (Fig. 3G), and [Ca²⁺]_C (Fig. 3H). The drug did not affect the bradykinin-induced increase in [Ca²⁺]_M in control fibroblasts but completely restored this parameter in patient cells (peak values of 4.21 ± 0.13 µM and 4.06 ± 0.13 µM for CGP37157treated control (n = 6) and patient (n = 6) cells, respectively) (Fig. 3E). Moreover, the drug significantly (p < 0.05) increased the half-time of the [Ca²⁺]_M decrease in both control and patient cells to 7.8 ± 0.5 s and 8.5 ± 0.7 s for control (n = 6) and patient (n = 6) cells, respectively. CGP37157did not alter the resting [Ca²⁺]_M.

Next, we addressed the question of whether restoration of mitochondrial Ca²⁺ uptake resulted in enhanced activation of the OXPHOS system. In patient fibroblasts, CGP37157increased both the rising speed and the peak value of the bradykinin-induced [ATP]_M increase to control values (rising speed of 0.31 ± 0.04%·s^–1 and peak value of 107.8 ± 0.6%, n = 5) (Fig. 3F). The drug did not affect these parameters in control cells (rising speed of 0.37 ± 0.03%·s^–1 and peak value of 109.4 ± 0.6%, n = 4). The restoration of agonist-induced mitochondrial ATP production was accompanied by an increase in rising speed and peak value of the [ATP]_C increase (rising speed of 0.17 ± 0.01%·s^–1 and peak value of 104.8 ± 0.3%, n = 4) (Fig. 3G). The drug did not significantly alter these parameters in control cells (rising speed of 0.18 ± 0.01%·s^–1 and peak value of 105.3 ± 0.4%, n = 4).

Finally, we investigated the effect of this drug on the bradykinin-induced [Ca²⁺]_C rise in Fura-2-loaded patient fibroblasts. CGP37157completely restored both the bradykinin-induced peak increase in [Ca²⁺]_C and the t of the subsequent [Ca²⁺]_C decrease to control values (maximum emission ratio of 5.4 ± 0.3 x base line and t value of 12.2 ± 0.7 s, n = 19) (Fig. 3H). The drug did not alter these parameters in control fibroblasts (maximum ratio value of 5.6 ± 0.3 x base line and t value of 11.5 ± 0.8 s, n = 18). The drug also did not alter the resting [Ca²⁺]_C.

CGP37157-induced Restoration of Cytosolic Ca²⁺ Handling in Complex I-deficient Fibroblasts Depends on the Mitochondrial Membrane Potential—To investigate the possible involvement of extracellular Ca²⁺ influx in the mechanism of action of CGP37157 Fura-2-loaded cells were stimulated in the absence of external Ca²⁺ (no Ca²⁺ added and 0.5 mM EGTA present). Also under these conditions patient fibroblasts displayed a decrease in bradykinin-induced peak [Ca²⁺]_C (Fig. 4A) and an increase in t of the subsequent [Ca²⁺]_C decrease (Fig. 4B) that were fully restored by CGP37157 These findings demonstrate that both the defect and its restoration by CGP37157are independent of external Ca²⁺. CGP37157did not change the area under the ionomycin-evoked [Ca²⁺]_C transient (97 ± 3% and 79 ± 3% for CGP37157treated control (n = 19) and patient (n = 29) fibroblasts, respectively) (Fig. 4C). This indicates that the drug does not affect the filling state of the internal Ca²⁺ stores.

The importance of _M for the restorative effect of CGP37157was investigated using the protonophore FCCP. FCCP, when added at a concentration of 1 µM, caused the complete loss of mitochondrial rhodamine 123 staining within 1 min after its addition, demonstrating the rapid breakdown of the mitochondrial membrane potential (data not shown). Within the same time frame, FCCP caused a marked decrease in [ATP]_M (Fig. 4D) and [ATP]_C (Fig. 4E). The ATP level before drug treatment was set at 100%, demonstrating that in both the mitochondrial matrix and cytoplasm the FCCP-induced decrease in ATP was higher in patient fibroblasts. Similarly, at 2 min after the onset of drug treatment the ATP level in both mitochondrial matrix and cytoplasm was 20% (p < 0.01) lower in patient fibroblasts (Fig. 4F).

Regarding the effect of FCCP on [Ca²⁺]_ER, only a small reduction was observed at 2 min after addition of the drug (Fig. 4C). In control cells this reduction was 11% (n = 22), whereas in patient cells this reduction was 5% (n = 28).

With respect to the bradykinin-induced [Ca²⁺]_C transient, pretreatment of control cells with 1 µM FCCP for 2 min significantly (p < 0.001) decreased the peak increase in [Ca²⁺]_C by 25% (Fig. 4A). In addition, the drug significantly (p < 0.001) slowed down the rate of cytosolic Ca²⁺ removal (Fig. 4B). Notably, the peak increase in [Ca²⁺]_C was exactly the same in FCCP-treated control and patient fibroblasts, indicating that 25% of the bradykinin-induced peak increase in [Ca²⁺]_C depends on an intact mitochondrial membrane potential. The observation that the peak [Ca²⁺]_C increase was decreased by 15% in patient fibroblasts (Fig. 4A) is in agreement with the idea that the mitochondrial membrane potential is partly reduced in these cells. FCCP did not significantly alter the rate of cytosolic Ca²⁺ removal in patient fibroblasts (Fig. 4B). Of note, the rate of cytosolic Ca²⁺ removal was still significantly higher in FCCP-treated control cells as compared with FCCP-treated patient cells (Fig. 4B). This is in line with the finding that the FCCP-induced decrease in both [ATP]_M and [ATP]_C is less in control cells as compared with patient cells (Fig. 4, D–F). Importantly, the restorative effect of CGP37157was completely abolished in FCCP-treated patient fibroblasts, indicating that an intact mitochondrial membrane potential is required for the drug to exert its effect (Fig. 4, A and B).

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Human complex I (NADH:ubiquinone oxidoreductase) deficiency leads to a wide variety of clinical disease presentations, of which the underlying cell biological causes are poorly understood (7). Here we show that mitochondrial membrane potential and, as a consequence, agonist-induced mitochondrial Ca²⁺ uptake and ensuing stimulation of mitochondrial ATP production are impaired in skin fibroblasts from a patient with Leigh disease carrying a homozygous missense mutation (G364A) in the nuclear NDUFS7 gene (4). We also show that the impairments in mitochondrial function are associated with a reduced filling state of the ER Ca²⁺ store, a decreased agonist-induced peak [Ca²⁺]_C increase, and a reduced rate of cytosolic Ca²⁺ removal following agonist stimulation. Given the unaltered capacity for ER Ca²⁺ uptake it seems unlikely that the reduced filling state of the ER Ca²⁺ store is because of changes in its physical size and/or the number and transport properties of the SERCA Ca²⁺ pumps; rather, the reduced filling state is secondary to changes in cellular ATP synthesis. Unexpectedly, we show that cytosolic ATP levels are lower in patient versus control cells even in the presence of high concentrations of a mitochondrial uncoupler, suggestive of extramitochondrial changes in ATP synthetic capacity. Although an exploration of the nature of these changes is beyond the scope of the present work, it is conceivable that decreases in glycolytic enzyme activity, enhanced activity of ATP-consuming mechanisms, or both are involved and represent cellular consequences of the decrease in mitochondrial oxidative capacity. Importantly, all aberrations, except for the decreased filling state of the ER, were completely restored upon acute inhibition of mitochondrial Na⁺-Ca²⁺ exchange by the benzothiazepine CGP37157 presumably acting to restore agonist-induced mitochondrial ATP synthesis and thus overcoming small differences in extramitochondrial ATP synthesis or consumption.

Growing evidence suggests that under certain circumstances agonist-induced Ca²⁺ signals can turn from a survival signal into a death signal (39). For instance, agonist-induced mitochondrial Ca²⁺ uptake may induce apoptosis by activation of the permeability transition pore in response to a variety of pathological conditions (40). The cellular and molecular mechanisms underlying this switch are just beginning to be understood. Thus, enhanced formation of superoxide and hydrogen peroxide has been demonstrated to promote the Ca²⁺-dependent opening of the permeability transition pore (41). Because the production of reactive oxygen species is increased in complex I-deficient cells (9), it is of importance to have detailed information about cytosolic and mitochondrial Ca²⁺ handling in cells with a malfunctioning complex I, especially under conditions of increased cytosolic Ca²⁺ mobilization as they occur during hormonal and electrical stimulation.

Decreased Agonist-induced Mitochondrial Ca²⁺ Uptake and Ensuing ATP Production Are Restored by CGP37157in Complex I-deficient Fibroblasts—Under non-pathological conditions, agonist-induced mitochondrial Ca²⁺ uptake leads to an increase in mitochondrial ATP production (12, 37) through the activation of mitochondrial dehydrogenases (35). Here we show that bradykinin-induced mitochondrial Ca²⁺ uptake and ATP production are decreased in fibroblasts from a patient with isolated complex I deficiency. Importantly, CGP37157restored the bradykinin-induced increase in both [Ca²⁺]_M and [ATP]_M, indicating that the reduction in mitochondrial ATP production observed in agonist-stimulated patient fibroblasts is because of a decrease in mitochondrial Ca²⁺ uptake. The reduction of the bradykinin-induced peak increase in [Ca²⁺]_M was only 20%, whereas the decrease in bradykinin-stimulated mitochondrial ATP production was 60%. This observation is in line with previous work showing that the agonist-induced increase in [ATP]_M was already abolished when the agonist-induced peak increase in [Ca²⁺]_M was reduced by no more than 40% (37). The increase in [ATP]_M started 20 s after the onset of stimulation. This lag time is in agreement with the finding that in hepatocytes the mitochondrial [NADH] increased during the first 30 s of stimulation, after which it decreased again as a result of respiratory chain activation (36). Previous work revealed that this period of increased respiratory chain activity outlasted the return of [Ca²⁺]_C and [Ca²⁺]_M to basal levels (19, 37).

Reduced Agonist-induced Increase in [Ca²+]_C Is Restored by CGP37157in Complex I Deficiency—Stimulations performed in the absence of external Ca²⁺ revealed that bradykinin increases [Ca²⁺]_C and, as a consequence, [Ca²⁺]_M by promoting the release of Ca²⁺ from the ER in human skin fibroblasts. Here we show that the filling state of the ER is significantly reduced in patient fibroblasts. The data presented show that this reduction is not because of a decrease in physical size of the store. Neither is this reduction because of a decrease in SERCA number and/or transport properties or an increase in Ca²⁺ leakage. Our finding that the cytosolic ATP level and, as a consequence, the rate of cytosolic Ca²⁺ removal are lower in FCCP-treated patient cells as compared with FCCP-treated control cells indicates that in patient cells glycolytic activity is decreased and/or that ATP consumption is increased. In untreated patient cells, these secondary effects of complex I deficiency may contribute to a decrease in SERCA-mediated filling of the ER Ca²⁺ store. Measurements performed with JC-1, a fluorescent dye that accumulates within the mitochondrial matrix as a function of _M (32), revealed that patient fibroblasts had a decreased resting _M. A similar observation was reached with patient fibroblasts carrying a mitochondrial tRNA^Leu mutation of MELAS (10). Because _M drives the activity of mitochondrial ATP synthase, it is likely that less ATP is produced at lower _M values. This, in turn, may lead to a decreased ATP supply to the SERCAs and, consequently, a decreased filling state of the ER. The total cellular ATP content was only slightly (5%) decreased in patient fibroblasts, a result that did not reach statistical significance. This finding suggests that the lower ER Ca²⁺ content observed in resting complex I-deficient fibroblasts is because of a reduced local supply of ATP from mitochondria to neighboring SERCA pumps.

It can be hypothesized that bradykinin releases less Ca²⁺ from the ER in patient fibroblasts and therefore evokes a reduced increase in [Ca²⁺]_C and, as a consequence, [Ca²⁺]_M in these cells. However, the present study shows that in untreated patient fibroblasts the ER Ca²⁺ content and bradykinin-induced peak increase in [Ca²⁺]_C were decreased by 21 and 13%, respectively, whereas in FCCP-treated control fibroblasts these values were 11 and 23%, respectively. Importantly, this finding indicates that the decrease in [Ca²⁺]_C observed following acute FCCP treatment cannot be because of a decrease in ER Ca²⁺ content alone. It has been demonstrated that the activity of the inositol 1,4,5-trisphosphate (InsP₃) receptors that mediate the agonist-induced release of Ca²⁺ from the ER is regulated by ambient [ATP]_C and [Ca²⁺]_C (42). Decreases in [ATP]_C have been shown to activate InsP₃-induced Ca²⁺ release. Here we show, however, that acute FCCP treatment, despite causing a dramatic decrease in [ATP]_C, decreased rather than increased the bradykinin-induced increase in [Ca²⁺]_C. Other studies have shown that the activity of InsP₃ receptors is inhibited at high ambient [Ca²⁺]_C (28, 43–45). This opens the possibility that FCCP, by abolishing mitochondrial Ca²⁺ uptake, causes a buildup of the cytosolic Ca²⁺ concentration in the mouth of the InsP₃-operated Ca²⁺ channels to levels that inhibit the Ca²⁺ release process, thereby reducing the total amount of Ca²⁺ that is released from the ER into the cytosol (46). It should be noted that this buildup of the cytosolic Ca²⁺ concentration during agonist stimulation is likely to be enhanced by the dramatic reduction in [ATP]_C and consequent decrease in SERCA-mediated Ca²⁺ uptake into the ER.

FCCP abolishes both the _M (complete loss of mitochondrial rhodamine 123 and JC-1 staining) and the bradykinin-induced increase in [Ca²⁺]_M. Based on these data we hypothesize that a decrease in _M, as observed in complex I-deficient fibroblasts, causes a decrease in mitochondrial Ca²⁺ uptake and thus contributes to a decrease in InsP₃-mediated Ca²⁺ release. Also in this case, the buildup of the cytosolic Ca²⁺ concentration in the mouth of the InsP₃-operated Ca²⁺ channels may be enhanced by a reduced supply of ATP to the SERCAs.

The finding that inhibition of mitochondrial Na⁺-Ca²⁺ exchange restores the peak increase in [Ca²⁺]_C provides us with intriguing information about the interplay between neighboring ER Ca²⁺ channels and mitochondrial Ca²⁺ uptake and extrusion sites (47). According to the above hypothesis, the restorative action of CGP37157in patient fibroblasts can be explained in that the drug by inhibiting mitochondrial Ca²⁺ release enhances the bradykinin-induced increase in [Ca²⁺]_M and consequent increases in dehydrogenase activity, _M, and ATP production. It is tempting to speculate that the increase in _M promotes further Ca²⁺ uptake thus preventing the buildup of inhibitory cytosolic Ca²⁺ concentrations in the mouth of the InsP₃-operated Ca²⁺ channels. As a consequence, more Ca²⁺ is released from the ER into the cytoplasm leading to restoration of the bradykinin-induced increase in [Ca²⁺]_C. Notably, acute treatment with CGP37157did not restore the ER Ca²⁺ content in complex I-deficient fibroblasts, whereas it restored the bradykinin-induced increases in [Ca²⁺]_C and [Ca²⁺]_M in these cells. This observation reinforces the idea that CGP37157exerts its restorative effect by increasing _M. It is unlikely that CGP37157exerts this effect through its stimulatory action on mitochondrial ATP production and consequent SERCA activation because the increases in [ATP]_M and [ATP]_C clearly lag behind the increase in [Ca²⁺]_C. Finally, the observation that FCCP abolished the restorative effect of CGP37157furthermore stresses the importance of _M in the mechanism of action of this drug.

Decreased Cytosolic Ca²⁺ Removal following Agonist Stimulation and Its Restoration by CGP37157in Complex I Deficiency—A significant correlation was observed between the rate of cytosolic Ca²⁺ removal and the peak increase in [Ca²⁺]_C in bradykinin-stimulated patient fibroblasts, indicating a common cause for their reduction in human complex I deficiency. Similarly to four of the eight patient cell lines studied here, the agonist-induced peak increase in [Ca²⁺]_C was not altered in a cybrid cell line of ⁰-osteosarcoma cells and enucleated cytoplasts from a patient with the tRNA^Lys mutation of MERRF (12). However, in the latter study no analysis of the rate of cytosolic Ca²⁺ removal was performed. Here we show that this rate was significantly decreased in all eight complex I-deficient cell lines tested. In addition we show that acute addition of CGP37157can restore the rate of cytosolic Ca²⁺ removal in patient fibroblasts. Based on our findings, this effect of the drug is explained in that it restores mitochondrial ATP production and thus cytosolic ATP supply to the SERCAs.

As a consequence of decreased agonist-induced mitochondrial ATP production, fueling of energy-requiring processes, set in motion by the increase in [Ca²⁺]_C, becomes jeopardized. One of these processes is the energy-dependent extrusion of Ca²⁺ from the cytosolic compartment. Indeed, the present study shows that this process is significantly slowed down in bradykinin-stimulated patient fibroblasts. We demonstrated recently that the rate of sarcoplasmic Ca²⁺ removal following electrical stimulation was significantly reduced in myotubes cultured from the quadriceps muscle of patients with an adult onset of exercise intolerance and exercise-induced myalgia and stiffness exhibiting a biochemically defined decrease in mitochondrial ATP production capacity (48). It is tempting to speculate that in the long term, the cumulative effect of such longer lasting [Ca²⁺]_C rises is toxic to the cell. It has been demonstrated that sustained elevations of [Ca²⁺]_C can switch on a number of mechanisms leading to necrotic as well as apoptotic cell death (49–51). The present finding that CGP37157can normalize the rate of cytosolic Ca²⁺ removal by restoring mitochondrial ATP synthesis in complex I-deficient patient fibroblasts may open possibilities of future therapeutic treatment. In this context, it is of importance to realize that the drug did not affect the rate of cytosolic Ca²⁺ removal in fibroblasts from a healthy subject.

Conclusions—Intriguingly, although the OXPHOS system contains a defective complex I, it was possible to enhance mitochondrial ATP synthesis by acute treatment with CGP37157 It is of note that enzymatic deficiencies in different parts of the energy-producing cascade, like the pyruvate dehydrogenase complex, complex I, and complex IV of the OXPHOS system, may all lead to Leigh disease. It is therefore tempting to assume that Leigh disease, although genetically different, has a similar underlying pathophysiological basis of which Ca²⁺ may be the common denominator.

	FOOTNOTES

 
^* This work was supported by 6th Framework Programma Integrated Project Grant LSHM-CT-2004-503116 from the European Community and a Van Walree Fund grant from the Royal Netherlands Academy of Arts and Sciences. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by Wellcome Trust Research Leave Fellowship and Programme Grant 067081/Z/02/Z, the Human Frontiers Science Program, the Medical Research Council (United Kingdom), and Diabetes UK.

^¶¶ To whom correspondence should be addressed: Nijmegen Center for Mitochondrial Disorders, Dept. of Pediatrics, University Medical Center Nijmegen, P. O. Box 9101, NL-6500 HB Nijmegen, The Netherlands. Tel.: 31-243614430; Fax: 31-243616428; E-mail: j.smeitink{at}cukz.umcn.nl.

¹ The abbreviations used are: OXPHOS, oxidative phosphorylation; NDUFS7, NADH dehydrogenase ubiquinone flavoprotein S7 subunit; BHQ, 2,5-di-tert-butyl-benzohydroquinone; FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone; MELAS, myopathy, encephalopathy, lactic acidosis, stroke-like episodes; MERRF, myoclonic epilepsy with ragged red fibers; [Ca²⁺]_C, [Ca²⁺]_ER, and [Ca²⁺], cytosolic, endoplasmic reticular, and mitochondrial free Ca²⁺ concentrations; [ATP]_C and [ATP]_M, cytosolic and mitochondrial ATP concentrations; ER, endoplasmic reticulum; InsP₃, inositol 1,4,5-trisphosphate; CMV, cytomegalovirus; KRB, Krebs-Ringer bicarbonate medium; SERCA, sarco(endo)plasmic reticulum Ca²⁺-ATPase.

² J. A. M. Smeitink and L. P. van den Heuvel, unpublished data.

	ACKNOWLEDGMENTS

 
We thank Dr. Gabriela Da SilvaXavier (University of Bristol), Dr. Takashi Tsuboi (University of Bristol), and Martijn Wilmer (Department of Pediatrics, University Medical Center Nijmegen) for technical assistance.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Loeffen, J., Elpeleg, O., Smeitink, J., Smeets, R., Stöckler-Ipsiroglu, S., Mandel, H., Sengers, R., Trijbels, F., and van den Heuvel, L. (2001) Ann. Neurol. 49, 195–201[CrossRef][Medline] [Order article via Infotrieve]
2. Budde, S. M. S., van den Heuvel, L. P. W. J., Janssen, A. J., Smeets, R. J. P., Buskens, C. A. F., DeMeirleir, L., van Coster, R., Baethmann, M., Voit, T., Trijbels, J. M. F., and Smeitink, J. A. M. (2000) Biochem. Biophys. Res. Commun. 275, 63–68[CrossRef][Medline] [Order article via Infotrieve]
3. Van den Heuvel, L., Ruitenbeek, W., Smeets, R., Gelman-Kohan, Z., Elpeleg, O., Loeffen, J., Trijbels, F., Mariman, E., de Bruijn, D., and Smeitink, J. (1998) Am. J. Hum. Genet. 62, 262–268[CrossRef][Medline] [Order article via Infotrieve]
4. Triepels, R. H., van den Heuvel, J. P., Loeffen, J. L. C. M., Buskens, C. A. F., Smeets, R. J. P., Rubio Gozalbo, M. E., Budde, S. M. S., Mariman, E. C., Wijburg, F. A., Barth, P. G., Trijbels, J. M. F., and Smeitink, J. A. M. (1999) Ann. Neurol. 45, 787–790[CrossRef][Medline] [Order article via Infotrieve]
5. Loeffen, J., Smeitink, J., Triepels, R., Smeets, R., Schuelke, M., Sengers, R., Trijbels, F., Hamel, B., Mullaart, R., and van den Heuvel, L. (1998) Am. J. Hum. Genet. 63, 1598–1608[CrossRef][Medline] [Order article via Infotrieve]
6. Schuelke, M., Smeitink, J., Mariman, E., Loeffen, J., Plecko, B., Trijbels, F., Stöckler-Ipsiroglu, S., and van den Heuvel, L. (1999) Nat. Genet. 21, 260–261[CrossRef][Medline] [Order article via Infotrieve]
7. Smeitink, J., van den Heuvel, L., and DiMauro, S. (2001) Nat. Rev. Genet. 2, 342–352[CrossRef][Medline] [Order article via Infotrieve]
8. Robinson, B. H., Glerum, D. M., Chow, W., Petrova-Benedict, R., Lightowlers, R., and Capaldi, R. (1990) Pediatr. Res. 28, 549–555[Medline] [Order article via Infotrieve]
9. Pitkänen, S., and Robinson, B. H. (1996) J. Clin. Investig. 98, 345–351[Medline] [Order article via Infotrieve]
10. Moudy, A. M., Handran, S. D., Goldberg, M. P., Ruffin, N., Karl, I., Kranz-Eble, P., DeVivo, D. C., and Rothman, S. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 729–733[Abstract/Free Full Text]
11. Vazquez-Memije, M. E., Shanske, S., Santorelli, F. M., Kranz-Eble, P., Davidson, E., DeVivo, D. C., and DiMauro, S. (1996) J. Inherit. Metab. Dis. 19, 43–50[CrossRef][Medline] [Order article via Infotrieve]
12. Brini, M., Pinton, P., King, M. P., Davidson, M., Schon, E. A., and Rizzuto, R. (1999) Nat. Med. 5, 951–954[CrossRef][Medline] [Order article via Infotrieve]
13. Carrozzo, R., Tessa, A., Vázquez-memije, M. E., Piemonte, F., Patrono, C., Malandrini, A., Dionisi-Vici, C., Vilarinho, L., Villanova, M., Schägger, H., Federico, A., Bertini, E., and Santorelli, F. M. (2001) Neurology 56, 687–690[Abstract/Free Full Text]
14. Van der Westhuizen, F. H., van den Heuvel, L. P., Smeets, R., Veltman, J. A., Pfundt, R., van Kessel, A. G., Ursing, B. M., and Smeitink, J. A. M. (2003) Neuropediatrics 34, 14–22[CrossRef][Medline] [Order article via Infotrieve]
15. Ahlers, P. M., Garofano, A., Kerscher, S. J., and Brandt, U. (2000) Biochim. Biophys. Acta 1459, 258–265[Medline] [Order article via Infotrieve]
16. Weidner, U., Geier, S., Ptock, A., Friedrich, T., and Weiss, H. (1993) J. Mol. Biol. 233, 109–122[CrossRef][Medline] [Order article via Infotrieve]
17. Ahlers, P. M., Zwicker, K., Kerscher, S., and Brandt, U. (2000) J. Biol. Chem. 275, 23577–23582[Abstract/Free Full Text]
18. Koopman, W. J. H., Bosch, R. R., van Emst-de Vries, S. E., Spaargaren, M., De Pont, J. J. H. H. M., and Willems, P. H. G. M. (2003) J. Biol. Chem. 278, 13672–13679[Abstract/Free Full Text]
19. Ainscow, E. K., and Rutter, G. A. (2001) Biochem. J. 353, 175–180[CrossRef][Medline] [Order article via Infotrieve]
20. Ainscow, E. K., and Rutter, G. A. (2002) Diabetes 51, S162–S170[Abstract/Free Full Text]
21. Montero, M., Brini, M., Marsault, R., Alvarez, J., Sitia, R., Pozzan, T., and Rizzuto, R. (1995) EMBO J. 14, 5467–5475[Medline] [Order article via Infotrieve]
22. Rutter, G. A., Theler, J. M., Murgia, M., Wollheim, C. B., Pozzan, T., and Rizzuto, R. (1993) J. Biol. Chem. 268, 22385–22390[Abstract/Free Full Text]
23. Brini, M., Marsault, R., Bastianutto, C., Alvarez, J., Pozzan, T., and Rizzuto, R. (1995) J. Biol. Chem. 270, 9896–9903[Abstract/Free Full Text]
24. van de Put, F. H., De Pont, J. J. H. H. M., and Willems, P. H. G. M. (1994) J. Biol. Chem. 269, 12438–12443[Abstract/Free Full Text]
25. Alvarez, J., and Montero, M. (2002) Cell Calcium 32, 251–260[CrossRef][Medline] [Order article via Infotrieve]
26. Assimacopolous-Jeannet, F., McCormack, J. G., and Jeanrenaud, B. (1986) J. Biol. Chem. 261, 8799–8804[Abstract/Free Full Text]
27. Rizzuto, R., Simpson, A. W. M., Brini, M., and Pozzan, T. (1992) Nature 358, 325–327[CrossRef][Medline] [Order article via Infotrieve]
28. Rizzuto, R., Brini, M., Murgia, M., and Pozzan, T. (1993) Science 262, 744–747[Abstract/Free Full Text]
29. Gunter, K. K., and Gunter, T. E. (1994) J. Bioenerg. Biomembr. 26, 471–485[CrossRef][Medline] [Order article via Infotrieve]
30. Bernardi, P. (1999) Physiol. Rev. 79, 1127–1155[Abstract/Free Full Text]
31. Kirichok, Y., Krapivinsky, G., and Clapham, D. E. (2004) Nature 427, 360–364[CrossRef][Medline] [Order article via Infotrieve]
32. Smiley, S. T., Reers, M., Mottola-Hartshorn, C., Lin, M., Chen, A., Smith, T. W., Steele, G. D., and Chen, L. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3671–3675[Abstract/Free Full Text]
33. Denton, R. M., and McCormack, J. G. (1990) Annu. Rev. Physiol. 52, 451–466[CrossRef][Medline] [Order article via Infotrieve]
34. Rutter, G. A. (1990) Int. J. Biochem. 22, 1081–1088[CrossRef][Medline] [Order article via Infotrieve]
35. Hajnóczky, G., Robb-Gaspers, L. D., Seitz, M. B., and Thomas, A. P. (1995) Cell 85, 415–424
36. Robb-Gaspers, L. D., Burnett, P., Rutter, G. A., Denton, R. M., Rizzuto, R., and Thomas, A. P. (1998) EMBO J. 17, 4987–5000[CrossRef][Medline] [Order article via Infotrieve]
37. Jouaville, L. S., Pinton, P., Bastianutto, C., Rutter, G. A., and Rizzuto, R. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13807–13812[Abstract/Free Full Text]
38. Cox, D. A., and Matlib, M. A. (1993) J. Biol. Chem. 268, 938–947[Abstract/Free Full Text]
39. Orrenius, S., Zhivotovsky, B., and Nicotera, P. (2003) Nat. Rev. Mol. Cell Biol. 4, 552–565[CrossRef][Medline] [Order article via Infotrieve]
40. Hajnoczky, G., Davies, E., and Madesh, M. (2003) Biochem. Biophys. Res. Commun. 304, 445–454[CrossRef][Medline] [Order article via Infotrieve]
41. Madesh, M., and Hajnoczky, G. (2001) J. Cell Biol. 155, 1003–1015[Abstract/Free Full Text]
42. Patel, S., Joseph, S. K., and Thomas, A. P. (1999) Cell Calcium 25, 247–264[CrossRef][Medline] [Order article via Infotrieve]
43. Rizzuto, R., Bastianutto, C., Brini, M., Murgia, M., and Pozzan, T. (1994) J. Cell Biol. 126, 1183–1194[Abstract/Free Full Text]
44. Rapizzi, E., Pinton, P., Szabadkai, G., Wieckowski, M. R., Vandecasteele, G., Baird, G., Tuft, R. A., and Fogarty, K. E. (2002) J. Cell Biol. 159, 613–624[Abstract/Free Full Text]
45. Szabadkai, G., Simoni, A. M., and Rizzuto, R. (2003) J. Biol. Chem. 278, 15153–15161[Abstract/Free Full Text]
46. Bezprozvanny, I., Watras, J., and Ehrlich, B. E. (1991) Nature 351, 751–754[CrossRef][Medline] [Order article via Infotrieve]
47. Csordas, G., Thomas, A. P., and Hajnoczky, G. (1999) EMBO J. 18, 96–108[CrossRef][Medline] [Order article via Infotrieve]
48. Koopman, W. J. H., Renders, M., Oosterhof, A., van Kuppevelt, T. M., van Engelen, B. G., and Willems, P. H. G. M. (2003) Am. J. Physiol. Cell Physiol. 285, C1263–C1269[Abstract/Free Full Text]
49. Khan, A. A., Soloski, M. J., Sharp, A. H., Schilling, G., Sabatini, D. M., Li, S. H., Ross, C. A., and Snyder, S. H. (1996) Science 273, 503–507[Abstract]
50. Nicotera, P., and Orrenius, S. (1998) Cell Calcium 23, 173–180[CrossRef][Medline] [Order article via Infotrieve]
51. Wang, H. G., Pathan, N., Ethell, I. M., Krajewski, S., Yamaguchi, Y., Shibasaki, F., McKeon, F., Bobo, T., Franke, T. F., and Reed, J. C. (1999) Science 284, 339–343[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				F. Distelmaier, W. J.H. Koopman, L. P. van den Heuvel, R. J. Rodenburg, E. Mayatepek, P. H.G.M. Willems, and J. A.M. Smeitink Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease Brain, April 1, 2009; 132(4): 833 - 842. [Abstract] [Full Text] [PDF]

				K. J. Menzies, B. H. Robinson, and D. A. Hood Effect of thyroid hormone on mitochondrial properties and oxidative stress in cells from patients with mtDNA defects Am J Physiol Cell Physiol, February 1, 2009; 296(2): C355 - C362. [Abstract] [Full Text] [PDF]

				W. J. H. Koopman, F. Distelmaier, M. A. Hink, S. Verkaart, M. Wijers, J. Fransen, J. A. M. Smeitink, and P. H. G. M. Willems Inherited complex I deficiency is associated with faster protein diffusion in the matrix of moving mitochondria Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1124 - C1132. [Abstract] [Full Text] [PDF]

				W. J. H. Koopman, S. Verkaart, H. J. Visch, S. van Emst-de Vries, L. G. J. Nijtmans, J. A. M. Smeitink, and P. H. G. M. Willems Human NADH:ubiquinone oxidoreductase deficiency: radical changes in mitochondrial morphology? Am J Physiol Cell Physiol, July 1, 2007; 293(1): C22 - C29. [Abstract] [Full Text] [PDF]

				H.-J. Visch, W. J. H. Koopman, D. Zeegers, S. E. van Emst-de Vries, F. J. M. van Kuppeveld, L. W. P. J. van den Heuvel, J. A. M. Smeitink, and P. H. G. M. Willems Ca2+-mobilizing agonists increase mitochondrial ATP production to accelerate cytosolic Ca2+ removal: aberrations in human complex I deficiency Am J Physiol Cell Physiol, August 1, 2006; 291(2): C308 - C316. [Abstract] [Full Text] [PDF]

				A. Wiederkehr and C. B. Wollheim Minireview: Implication of Mitochondria in Insulin Secretion and Action Endocrinology, June 1, 2006; 147(6): 2643 - 2649. [Abstract] [Full Text] [PDF]

				J. H. Robben, M. Sze, N.V.A.M. Knoers, and P.M.T. Deen Rescue of Vasopressin V2 Receptor Mutants by Chemical Chaperones: Specificity and Mechanism Mol. Biol. Cell, January 1, 2006; 17(1): 379 - 386. [Abstract] [Full Text] [PDF]

				W. J. H. Koopman, H.-J. Visch, S. Verkaart, L. W. P. J. van den Heuvel, J. A. M. Smeitink, and P. H. G. M. Willems Mitochondrial network complexity and pathological decrease in complex I activity are tightly correlated in isolated human complex I deficiency Am J Physiol Cell Physiol, October 1, 2005; 289(4): C881 - C890. [Abstract] [Full Text] [PDF]

				W. J. H. Koopman, S. Verkaart, H.-J. Visch, F. H. van der Westhuizen, M. P. Murphy, L. W. P. J. van den Heuvel, J. A. M. Smeitink, and P. H. G. M. Willems Inhibition of complex I of the electron transport chain causes O2-{middle dot}-mediated mitochondrial outgrowth Am J Physiol Cell Physiol, June 1, 2005; 288(6): C1440 - C1450. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 279/39/40328    most recent M408068200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Visch, H.-J. Articles by Willems, P. H. G. M. Search for Related Content PubMed PubMed Citation Articles by Visch, H.-J. Articles by Willems, P. H. G. M. Social Bookmarking                      What's this?